T-DXd is currently under investigation in a phase 2 trial, in patients with HER2-expressing metastatic colorectal cancer that progressed on ≥2 prior systemic treatment regimens (DESTINY-CRC01, NCT03384940) (Table 2). Here, ERBB2 is linked to metastatic colorectal cancer.